Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 - Increase in Patient Pool a Market Driver

News provided by

Research and Markets

07 Sep, 2015, 15:10 GMT

DUBLIN, Sept. 07, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/v9t2rl/global_chronic) has announced the addition of the "Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019" report to their offering.

Continue Reading
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

The global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

This report presents a scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.

Vendors are increasingly forming strategic alliances to increase their market shares. Co-development agreements allow the sharing of regulatory and developmental experiences gained by either company to support pipeline candidates.

According to the report, The increase in the patient pool for chronic lymphocytic leukemia is a major driver of the market. The elderly are more likely to be diagnosed with chronic lymphocytic leukemia. The older adult population is increasing globally, which indicates that the probability of getting chronic lymphocytic leukemia is also rising. As a result, the consumption of medications will increase, which will generate substantial revenue in the market.

Further, the report states that the unknown etiology of chronic lymphocytic leukemia is a major challenge because vendors are unable to target the basic cause of the disease. This makes it difficult for them to develop a drug that can effectively treat and cure the disease.

Based on the type of molecule, we group the market into two categories:

  • Biologics
  • Small molecules

Based on the route of administration, we group the market into two:

  • Oral
  • Parenteral

Key Vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Actavis
  • Amgen
  • Aryogen
  • Astellas
  • Bristol-Myers Squibb
  • Eagle Pharmaceuticals
  • Eisai
  • Fresenius Kabi
  • Genmab
  • Gilead Sciences
  • H. Lundbeck
  • Hospira
  • idd biotech
  • Immunomedics
  • Johnson & Johnson
  • Mundipharma
  • Mylan
  • Noxxon
  • Ono Pharmaceutical
  • PDL BioPharma
  • Pfizer
  • Pharmacyclics
  • Regeneron
  • Sagent Pharmaceutical
  • Sanofi
  • SymBio Pharmaceuticals
  • TheraMAB

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Product Profiles
  5. Market Research Methodology
  6. Disease Overview
  7. Introduction
  8. Market Landscape
  9. Pipeline Portfolio
  10. Market Segmentation by Route of Administration
  11. Market Segmentation by Type of Molecule
  12. Geographical Segmentation
  13. Buying Criteria
  14. Market Growth Drivers
  15. Drivers and their Impact
  16. Market Challenges
  17. Impact of Drivers and Challenges
  18. Market Trends
  19. Trends and their Impact
  20. Vendor Landscape
  21. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/v9t2rl/global_chronic

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com